01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Cigna Group (CI) reported a net loss of $277 milliona, or -$0.97 per diluted share, for the first quarter of 2024, a significant decline from a net income of $1.3 billion, or $4.24 per diluted share, in the same period last year.
This net loss was primarily driven by a substantial $1.8 billionb net realized investment loss, largely due to an impairment of equity securities, specifically its investment in VillageMD. Despite the GAAP net loss, the company's adjusted income from operations, a non-GAAP measure, increased by 16% to $1.875 billion, or $6.47 per diluted share, reflecting the underlying operational strength of its Evernorth Health Services and Cigna Healthcare segments. Total revenues saw a significant increase of 23% to $57.3 billion, driven by a 31% surge in pharmacy revenues, largely attributed to the onboarding of Centene.
The Cigna Healthcare segment's adjusted revenues grew 4%, supported by higher premium rates. The company also announced its agreement to sell its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation (HCSC) for approximately $3.3 billionc, expected to close in Q1 2025. This strategic divestiture, coupled with robust operational performance in its core segments, positions Cigna for future focus and potential capital deployment.
02—Key points
Key Highlights
- Reported a GAAP net loss of $277 million ($0.97 per share) for Q1 2024, compared to net income of $1.3 billion ($4.24 per share) in Q1 2023, largely due to a significant $1.8 billion realized investment loss from equity security impairments.
- Adjusted income from operations increased 16% to $1.875 billion ($6.47 per share), indicating strong underlying business performance, driven by growth in both Evernorth Health Services and Cigna Healthcare segments.
- Total revenues surged 23% to $57.3 billion, primarily fueled by a 31% increase in pharmacy revenues, notably from onboarding Centene.
- Agreed to sell its Medicare Advantage and related businesses to HCSC for approximately $3.3 billion, expected to close in Q1 2025, streamlining its business portfolio.
- Cigna Healthcare segment saw adjusted revenues grow 4% and pre-tax adjusted income from operations increase 20%, driven by higher premium rates and a lower medical care ratio.
- Evernorth Health Services segment's adjusted revenues increased 28% and pre-tax adjusted income from operations grew 3%, benefiting from higher claims volume and specialty services growth.
- The company repurchased approximately $3.4 billion of common stock in Q1 2024, including initial deliveries under accelerated share repurchase agreements, demonstrating a commitment to returning capital to shareholders.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q1 FY2024, Cigna Group lost $0.00.
- Revenue$57.26B100.0%
- Cost of revenue−$41.43B72.4%
- Gross profit$15.82B27.6%
- Operating costs−$13.57B23.7%
- Operating income$2.26B3.9%
- Interest, other & tax−$2.53B4.4%
- Net income−$277.0M0.5%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 2, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $57.26B$46.52B | +23.1% |
| Cost of Revenue | $41.43B$31.46B | +31.7% |
| Gross Profit | $15.82B$15.06B | +5.1% |
| SG&A Expenses | $3.71B$3.54B | +4.7% |
| Operating Income | $2.26B$2.02B | +12.0% |
| Interest Expense | $369.00M$345.00M | +7.0% |
| Net Income | -$277.00M$1.27B | −121.9% |
| EPS (Basic) | $-0.97$4.28 | −122.7% |
| EPS (Diluted) | $-0.97$4.24 | −122.9% |
| Shares Outstanding (Diluted) | 286.46M299.00M | −4.2% |
05—Questions
Frequently Asked Questions
What caused the significant net loss in the first quarter of 2024?
The company reported a GAAP net loss of $277 million for the first quarter of 2024 primarily due to a substantial $1.8 billion net realized investment loss. This loss was mainly driven by the impairment of equity securities, notably the company's investment in VillageMD.
How did Cigna's operational performance fare despite the net loss?
Despite the GAAP net loss, Cigna's operational performance, as measured by adjusted income from operations, showed strength. Adjusted income from operations increased by 16% year-over-year to $1.875 billion, reflecting solid performance in its key business segments, particularly Evernorth Health Services and Cigna Healthcare.
What is the strategic significance of the announced sale of the Medicare Advantage business?
The announced sale of the Medicare Advantage and related businesses to HCSC for approximately $3.3 billion, expected to close in the first quarter of 2025, represents a strategic move to streamline Cigna's business portfolio. This divestiture allows the company to focus on its core Evernorth Health Services and Cigna Healthcare segments and potentially redeploy capital.
How did the company's revenue performance evolve in the first quarter?
Total revenues increased significantly by 23% to $57.3 billion. This growth was largely driven by a 31% increase in pharmacy revenues, which benefited from the onboarding of Centene at the beginning of 2024. The Cigna Healthcare segment also contributed with a 4% increase in adjusted revenues, supported by higher premium rates.
06—Continue